Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for ...

Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

AI agents will play a vital role in software programming and cybersecurity, but they will also change enterprise workflows ...

Spanish drugmaker PharmaMar Group today said it has received a payment of $10 million from Janssen Products, a Johnson & ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, ...

The National Systems Contractors Association (NSCA), together with Ignite, brought the inaugural Excellence in Business ...

That’s why the Sturgeon Bay theater company is giving the public a glimpse behind the curtain with a new TAP Talks series.

Pharma Mar SA (ES:PHM) has released an update. Pharma Mar S.A. has received a significant payment of $10 million from Janssen ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO ...